Incidence, Etiology, Prevention and Management of Ureteroenteric Strictures after Robot-Assisted Radical Cystectomy: A Review of Published Evidence and Personal Experience.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
13 10 2021
Historique:
received: 05 09 2021
revised: 07 10 2021
accepted: 11 10 2021
entrez: 22 10 2021
pubmed: 23 10 2021
medline: 28 10 2021
Statut: epublish

Résumé

Benign ureteroenteric anastomosis strictures (UESs) are one of many critical complications that may cause irreversible disability following robot-assisted radical cystectomy (RARC). Previous studies have shown that the incidence rates of UES after RARC can reach 25.3%, with RARC having higher UES incidence rates compared to open radical cystectomy. Various known and unknown factors are involved in the occurrence of UES. To minimize the incidence of UES after RARC, our group has standardized the procedure and technique for intracorporeal urinary diversion by applying the following five strategies: (1) wide delicate dissection of the ureter and preservation of the periureteral tissues; (2) gentle handling of the ureter and security of periureteral tissues at the anastomotic site; (3) use of indocyanine green to confirm good blood supply; (4) standardization of the ample ureteral spatulation length for Wallace ureteroenteric anastomosis through objective measurements; and (5) development of an institutional standardized procedure manual. This review focused on the incidence, etiology, prevention, and management of UES after RARC to bring attention to the incidence of this complication while also proposing standardized surgical procedures to minimize its incidence after RARC.

Identifiants

pubmed: 34677266
pii: curroncol28050348
doi: 10.3390/curroncol28050348
pmc: PMC8534632
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

4109-4117

Références

Eur Urol. 2012 Nov;62(5):806-13
pubmed: 22705382
Eur Urol. 2015 Mar;67(3):376-401
pubmed: 25560798
Eur Urol. 2009 Jan;55(1):164-74
pubmed: 18675501
BJU Int. 2021 Feb;127(2):182-189
pubmed: 32682331
J Urol. 2013 Feb;189(2):541-7
pubmed: 23260561
J Urol. 2011 Jun;185(6):2207-12
pubmed: 21497841
Lancet. 2018 Jun 23;391(10139):2525-2536
pubmed: 29976469
BJU Int. 2010 Mar;105(6):795-8
pubmed: 19725823
J Urol. 2011 Feb;185(2):562-7
pubmed: 21168867
Ther Adv Urol. 2019 Apr 04;11:1756287219839631
pubmed: 31057669
BMC Urol. 2019 Oct 24;19(1):100
pubmed: 31651306
Int J Urol. 2021 May;28(5):593-597
pubmed: 33594730
Can Urol Assoc J. 2015 May-Jun;9(5-6):E284-90
pubmed: 26029296
Urology. 2001 Dec;58(6):909-13
pubmed: 11744456
Eur Urol. 2021 Sep;80(3):366-373
pubmed: 33810922
Urology. 2011 Aug;78(2):459-65
pubmed: 21492915
Scand J Urol. 2018 Aug;52(4):244-248
pubmed: 30103644
Eur Urol. 2015 Jun;67(6):1042-1050
pubmed: 25496767
J Urol. 2003 Oct;170(4 Pt 1):1226-30
pubmed: 14501730
J Urol. 2008 Apr;179(4):1428-31
pubmed: 18289599
J Urol. 2017 Sep;198(3):567-574
pubmed: 28257782
J Urol. 2021 Apr;205(4):1119-1125
pubmed: 33249976
Int J Urol. 2017 May;24(5):390-395
pubmed: 28295645
J Urol. 2003 Mar;169(3):985-90
pubmed: 12576827
Urology. 2020 Oct;144:130-135
pubmed: 32653565
J Robot Surg. 2020 Aug;14(4):615-619
pubmed: 31586270
J Endourol. 2019 Oct;33(10):823-828
pubmed: 31397180
World J Urol. 2021 Jun;39(6):1903-1909
pubmed: 32747981
Eur Urol. 2016 Apr;69(4):613-621
pubmed: 26272237
Eur Urol Focus. 2021 Mar;7(2):352-358
pubmed: 32061537
J Endourol. 2012 Apr;26(4):372-6
pubmed: 22192112
Urology. 2020 Jan;135:57-65
pubmed: 31618656
Int J Urol. 2020 Mar;27(3):194-205
pubmed: 31981379
Urol Oncol. 2015 Feb;33(2):65.e1-8
pubmed: 25023788
Urology. 2018 Aug;118:e3-e4
pubmed: 29729367
Eur Urol. 2013 Oct;64(4):654-63
pubmed: 23769588
BJU Int. 2019 Aug;124(2):302-307
pubmed: 30815976
Urol Clin North Am. 2021 Feb;48(1):51-70
pubmed: 33218594
Int Braz J Urol. 2020 May-Jun;46(3):446-455
pubmed: 32167712
J Urol. 2006 Jul;176(1):161-6
pubmed: 16753394
J Urol. 2020 Mar;203(3):522-529
pubmed: 31549935
J Urol. 2007 Aug;178(2):538-42
pubmed: 17570422
J Laparoendosc Adv Surg Tech A. 2013 Jun;23(6):526-9
pubmed: 23531142

Auteurs

Shintaro Narita (S)

Department of Urology, School of Medicine, Akita University, Akita 010-8543, Japan.

Mitsuru Saito (M)

Department of Urology, School of Medicine, Akita University, Akita 010-8543, Japan.

Kazuyuki Numakura (K)

Department of Urology, School of Medicine, Akita University, Akita 010-8543, Japan.

Tomonori Habuchi (T)

Department of Urology, School of Medicine, Akita University, Akita 010-8543, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH